BTCC
/
BTCC Square
/
Global Cryptocurrency
/
FDA and OpenAI Explore AI-Driven Drug Review Acceleration
FDA and OpenAI Explore AI-Driven Drug Review Acceleration
10
1
The U.S. Food and Drug Administration is in talks with OpenAI to develop an AI tool aimed at streamlining drug evaluations. Dubbed ’cderGPT,’ the initiative targets the FDA’s Center for Drug Evaluation and Research, seeking to harness artificial intelligence for faster review processes.
FDA Commissioner Martin A. Makary has outlined aggressive plans to expand the agency’s AI adoption, with a deadline set for June 30. The MOVE reflects broader institutional interest in leveraging cutting-edge technology to enhance regulatory efficiency.
By:
Previous
Crypto Venture Funding Surges to $6B Despite Fewer Deals in Q1 2025
Next
NFT Marketplaces Compared: Where to Buy and Sell Digital Art
